Detrimental effects of adenosine signaling in sickle cell disease

Nature Medicine

Volumn 17, Issue 1, 2011, Pages 79-86

  Zhang, Yujin ^a   Dai, Yingbo ^a,b   Wen, Jiaming ^a,b   Zhang, Weiru ^a,c   Grenz, Almut ^d   Sun, Hong ^b   Tao, Lijian ^c   Lu, Guangxiu ^e   Alexander, Danny C ^f   Milburn, Michael V ^f   Carter Dawson, Louvenia ^a   Lewis, Dorothy E ^a   Zhang, Wenzheng ^a   Eltzschig, Holger K ^d   Kellems, Rodney E ^a   Blackburn, Michael R ^a   Juneja, Harinder S ^a   Xia, Yang ^a,e  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f METABOLON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; HEMOGLOBIN; PEGADEMASE; PSB 1115; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD LEVEL; CONTROLLED STUDY; ERYTHROCYTE; HEMATOLOGICAL PROCEDURES; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HUMAN CELL; KIDNEY FAILURE; METABOLOMICS; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION;

ADENOSINE; ADENOSINE DEAMINASE; ANEMIA, SICKLE CELL; ANIMALS; HEMOLYSIS; HUMANS; KIDNEY; LIVER; LUNG; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION; SPLEEN; XANTHINES;

MUS MUSCULUS;

EID: 78651245860     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2280     Document Type: Article

References (44)

1. Ingram, V.M. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 178, 792-794 (1956).
2. Madigan, C. & Malik, P. Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert Rev. Mol. Med. 8, 1-23 (2006).
3. Urbinati, F., Madigan, C. & Malik, P. Pathophysiology and therapy for haemoglobinopathies. Part II: thalassaemias. Expert Rev. Mol. Med. 8, 1-26 (2006).
4. Christoph, G.W., Hofrichter, J. & Eaton, W.A. Understanding the shape of sickled red cells. Biophys. J. 88, 1371-1376 (2005).
5. de Montalembert, M. Management of sickle cell disease. BMJ 337, a1397 (2008).
6. de Montalembert, M. Advances in sickle cell disease. Bull. Acad Natl. Med. 192, 1375-1381, discussion 1381 (2008).
7. Chui, D.H. & Dover, G.J. Sickle cell disease: no longer a single gene disorder. Curr. Opin. Pediatr. 13, 22-27 (2001).
8. Bunn, H.F. et al. Molecular and cellular pathogenesis of hemoglobin SC disease. Proc. Natl. Acad. Sci. USA 79, 7527-7531 (1982).
9. Ferrone, F.A. Polymerization and sickle cell disease: a molecular view. Microcirculation 11, 115-128 (2004).
10. Hebbel, R.P. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 77, 214-237 (1991).
11. Hebbel, R.P., Osarogiagbon, R. & Kaul, D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11, 129-151 (2004).
12. Pászty, C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr. Opin. Hematol. 4, 88-93 (1997).
13. Pászty, C. et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278, 876-878 (1997).
14. Fredholm, B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 14, 1315-1323 (2007).
15. Hershfield, M.S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 76, S228-S232 (1995).
16. Chan, B. et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin. Immunol. 117, 133-143 (2005).
17. Blackburn, M.R. et al. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J. Biol. Chem. 275, 32114-32121 (2000).
18. Scheinman, J.I. Sickle cell disease and the kidney. Nat. Clin. Pract. Nephrol. 5, 78-88 (2009).
19. Carbonaro, D.A. et al. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion. Blood 111, 5745-5754 (2008).
20. Carbonaro, D.A. et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol. Ther. 13, 1110-1120 (2006).
21. Wallace, K.L. et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 114, 667-676 (2009).
22. Narita, H., Yanagawa, S., Sasaki, R. & Chiba, H. Synthesis of 2,3-bisphosphoglycerate synthase in erythroid cells. J. Biol. Chem. 256, 7059-7063 (1981).
23. Sasaki, R. & Chiba, H. Functions and metabolism of 2,3-bisphosphoglycerate in erythroid cells. Tanpakushitsu Kakusan Koso 28, 957-973 (1983).
24. Sasaki, R. & Chiba, H. Role and induction of 2,3-bisphosphoglycerate synthase. Mol. Cell. Biochem. 53-54, 247-256 (1983).
25. Chiba, H. & Sasaki, R. Functions of 2,3-bisphosphoglycerate and its metabolism. Curr. Top. Cell. Regul. 14, 75-116 (1978).
26. Poillon, W.N., Kim, B.C., Labotka, R.J., Hicks, C.U. & Kark, J.A. Antisickling effects of 2,3-diphosphoglycerate depletion. Blood 85, 3289-3296 (1995).
27. Poillon, W.N. & Kim, B.C. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood 76, 1028-1036 (1990).
28. Poillon, W.N., Kim, B.C., Welty, E.V. & Walder, J.A. The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S. Arch. Biochem. Biophys. 249, 301-305 (1986).
29. Fredholm, B.B., AP, I.J., Jacobson, K.A., Klotz, K.N. & Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527-552 (2001).
30. Stiles, G.L. Adenosine receptor subtypes: new insights from cloning and functional studies. in Purinergic Approaches in Experimental Therapeutics (eds. Jacobson, K.A. & Jarvis, M.F.) 29-37 (Wiley-Liss, New York, 1997).
31. Palmer, T.M. & Stiles, G.L. Identification of an A2a adenosine receptor domain specifically responsible for mediating short-term desensitization. Biochemistry 36, 832-838 (1997).
32. Eltzschig, H.K. et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104, 3986-3992 (2004).
33. Eltzschig, H.K. et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Exp. Med. 198, 783-796 (2003).
34. Sebastiani, P. et al. A network model to predict the risk of death in sickle cell disease. Blood 110, 2727-2735 (2007).
35. Fung, E.B. et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am. J. Hematol. 82, 255-265 (2007).
36. Lanzkron, S., Haywood, C. Jr., Segal, J.B. & Dover, G.J. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am. J. Hematol. 81, 927-932 (2006).
37. Ballas, S.K. Current issues in sickle cell pain and its management. Hematology Am. Soc. Hematol. Educ. Program 2007, 97-105 (2007).
38. Mi, T. et al. Excess adenosine in murine penile erectile tissues contributes to priapism through A2B adenosine receptor signaling. J. Clin. Invest. 118, 1491-1501 (2008).
39. Wallace, K.L. & Linden, J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116, 5010-5020 (2010).
40. Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914 (2009).
41. Knudsen, T.B. et al. Effects of (R)-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse. Teratology 45, 91-103 (1992).
42. Perumbeti, A. et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114, 1174-1185 (2009).
43. Ericson, A. & de Verdier, C.H. A modified method for the determination of 2,3- diphosphoglycerate in erythrocytes. Scand. J. Clin. Lab. Invest. 29, 84-90 (1972).
44. Zhou, C.C. et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat. Med. 14, 855-862 (2008).